Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice

E. Boven, M. M. Nauta, H. M M Schluper, F. Elferink, W. J F Van Der Vijgh, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Five TNO platinum compounds were evaluated for antitumor activities in two human ovarian carcinoma tumor lines grown in nude mice. The most active drug, TNO-38, was investigated in five additional lines with a known range of sensitivity to cisplatin. None of the new compounds showed superior activity to cisplatin. The slightly lower activity of TNO-38 as compared to the parent compound was reproducible in all tumor lines. Besides the similarity in the antitumor activity, a remarkable correspondence in platinum distribution and retention at 24 hr of TNO-38 and cisplatin could be observed. Chromatographic analysis of the compounds in their injection fluids showed single peaks for TNO-26 and TNO-38. The degradation products of the latter drugs may have affected their activity and toxicity. These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1253-1260
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number10
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Platinum Compounds
Heterografts
Nude Mice
Ovarian Neoplasms
Cisplatin
Platinum
Pharmaceutical Preparations
Chromatography
Neoplasms
Carcinoma
Injections
TNO 38
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Boven, E., Nauta, M. M., Schluper, H. M. M., Elferink, F., Van Der Vijgh, W. J. F., & Pinedo, H. M. (1985). Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. European Journal of Cancer and Clinical Oncology, 21(10), 1253-1260. https://doi.org/10.1016/0277-5379(85)90023-9

Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. / Boven, E.; Nauta, M. M.; Schluper, H. M M; Elferink, F.; Van Der Vijgh, W. J F; Pinedo, H. M.

In: European Journal of Cancer and Clinical Oncology, Vol. 21, No. 10, 1985, p. 1253-1260.

Research output: Contribution to journalArticle

Boven, E, Nauta, MM, Schluper, HMM, Elferink, F, Van Der Vijgh, WJF & Pinedo, HM 1985, 'Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice', European Journal of Cancer and Clinical Oncology, vol. 21, no. 10, pp. 1253-1260. https://doi.org/10.1016/0277-5379(85)90023-9
Boven, E. ; Nauta, M. M. ; Schluper, H. M M ; Elferink, F. ; Van Der Vijgh, W. J F ; Pinedo, H. M. / Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. In: European Journal of Cancer and Clinical Oncology. 1985 ; Vol. 21, No. 10. pp. 1253-1260.
@article{afdfb7ebc19c466d9531bf86c5c41d5b,
title = "Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice",
abstract = "Five TNO platinum compounds were evaluated for antitumor activities in two human ovarian carcinoma tumor lines grown in nude mice. The most active drug, TNO-38, was investigated in five additional lines with a known range of sensitivity to cisplatin. None of the new compounds showed superior activity to cisplatin. The slightly lower activity of TNO-38 as compared to the parent compound was reproducible in all tumor lines. Besides the similarity in the antitumor activity, a remarkable correspondence in platinum distribution and retention at 24 hr of TNO-38 and cisplatin could be observed. Chromatographic analysis of the compounds in their injection fluids showed single peaks for TNO-26 and TNO-38. The degradation products of the latter drugs may have affected their activity and toxicity. These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer.",
author = "E. Boven and Nauta, {M. M.} and Schluper, {H. M M} and F. Elferink and {Van Der Vijgh}, {W. J F} and Pinedo, {H. M.}",
year = "1985",
doi = "10.1016/0277-5379(85)90023-9",
language = "English (US)",
volume = "21",
pages = "1253--1260",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "10",

}

TY - JOUR

T1 - Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice

AU - Boven, E.

AU - Nauta, M. M.

AU - Schluper, H. M M

AU - Elferink, F.

AU - Van Der Vijgh, W. J F

AU - Pinedo, H. M.

PY - 1985

Y1 - 1985

N2 - Five TNO platinum compounds were evaluated for antitumor activities in two human ovarian carcinoma tumor lines grown in nude mice. The most active drug, TNO-38, was investigated in five additional lines with a known range of sensitivity to cisplatin. None of the new compounds showed superior activity to cisplatin. The slightly lower activity of TNO-38 as compared to the parent compound was reproducible in all tumor lines. Besides the similarity in the antitumor activity, a remarkable correspondence in platinum distribution and retention at 24 hr of TNO-38 and cisplatin could be observed. Chromatographic analysis of the compounds in their injection fluids showed single peaks for TNO-26 and TNO-38. The degradation products of the latter drugs may have affected their activity and toxicity. These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer.

AB - Five TNO platinum compounds were evaluated for antitumor activities in two human ovarian carcinoma tumor lines grown in nude mice. The most active drug, TNO-38, was investigated in five additional lines with a known range of sensitivity to cisplatin. None of the new compounds showed superior activity to cisplatin. The slightly lower activity of TNO-38 as compared to the parent compound was reproducible in all tumor lines. Besides the similarity in the antitumor activity, a remarkable correspondence in platinum distribution and retention at 24 hr of TNO-38 and cisplatin could be observed. Chromatographic analysis of the compounds in their injection fluids showed single peaks for TNO-26 and TNO-38. The degradation products of the latter drugs may have affected their activity and toxicity. These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022386064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022386064&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(85)90023-9

DO - 10.1016/0277-5379(85)90023-9

M3 - Article

C2 - 4076289

AN - SCOPUS:0022386064

VL - 21

SP - 1253

EP - 1260

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 10

ER -